Elevated serum β2-glycoprotein-I-lipoprotein(a) complexes levels are associated with the presence and complications in type 2 diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 100, Issue 2, 2013, Pages 250-256

  Wang, Cheng ^a   Niu, Dong Mei ^a   Hu, Jing ^a   Guan, Xiao Cui ^a   Yang, Wen ^a   Wang, Jun Jun ^a   Zhang, Chen Yu ^a   Zhang, Chun Ni ^a  

^a NANJING UNIVERSITY   (China)

Author keywords

2 glycoprotein I; Complication; Lipoprotein(a); Oxidative modification; Type 2 diabetes mellitus

Indexed keywords

BETA2 GLYCOPROTEIN 1; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC FOOT; DIABETIC NEUROPATHY; DIABETIC PATIENT; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; BETA 2-GLYCOPROTEIN I; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; MIDDLE AGED;

EID: 84878357952     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2013.03.002     Document Type: Article

References (44)

1. Whiting D.R., Guariguata L., Weil C., Shaw J. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
2. Stamler J., Vaccaro O., Neaton J.D., Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993, 16:434-444.
3. Miao Y., Smink P.A., de Zeeuw D., Lambers Heerspink H.J. Drug-induced changes in risk/biomarkers and their relationship with renal and cardiovascular long-term outcome in patients with diabetes. Clin Chem 2011, 57:186-195.
4. Zavrelova H., Hoekstra T., Alssema M., Welschen L.M., Nijpels G., Moll A.C., et al. Progression and regression: district developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the diabetes care system west-friesland, the Netherlands. Diabetes Care 2011, 34:867-872.
5. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414:813-820.
6. Koenig W., Karakas M., Zierer A., Herder C., Baumert J., Meisinger C., et al. Oxidized LDL and the risk of coronary heart disease: results from the MONICA/KORA Augsburg Study. Clin Chem 2011, 57:1196-1200.
7. Matsuura E., Kobayashi K., Inoue K., Lopez L.R., Shoenfeld Y. Oxidized LDL/beta 2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 2005, 14:736-741.
8. Lopez L.R., Buckner T.R., Hurley B.L., Kobayashi K., Matsuura E. Determination of oxidized low-density lipoproteins (ox-LDL) versus ox-LDL/beta2GPI complexes for the assessment of autoimmune-mediated atherosclerosis. Ann N R Acad Sci 2007, 1109:303-310.
9. Lopez L.R., Hurley B.L., Simpson D.F., Matsuura E. Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus. Ann N R Acad Sci 2005, 1051:97-103.
10. Greco T.P., Conti-Kelly A.M., Anthony J.R., Greco T., Doyle R., Boisen M., et al. Oxidized-LDL/beta(2)-glycoprotein I complexes are associated with disease severity and increased risk for adverse outcomes in patients with acute coronary syndromes. Am J Clin Pathol 2010, 133:737-743.
11. Scanu A.M., Lawn R.M., Berg K. Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991, 115:209-218.
12. Jones G.T., Deng M., Hammond-Tooke G.D., McCormick S.P., van Rij A.M. Increased plasma lipoprotein(a) fond in large-artery atherosclerotic, but not small-artery occlusive, stroke. Clin Chem 2009, 55:1888-1890.
13. Wang J., Zhang C., Gong J., Zhu Y., Fu L., Wang X., et al. Development of new enzyme-linked immunosorbent assay for oxidized lipoprotein(a) by using purified human oxidized lipoprotein(a) autoantibodies as capture antibody. Clin Chim Acta 2007, 385:73-78.
14. Wollesen F., Dahlén G., Berglund L., Berne C. Peripheral atherosclerosis and serum lipoprotein(a) in diabetes. Diabetes Care 1999, 22:93-98.
15. Köchl S., Fresser F., Lobentanz E., Baier G., Utermann G. Novel interaction of apolipoprotein(a) with beta2-glycoprotein I mediated by the Kringle IV domain. Blood 1997, 90:1482-1489.
16. López-Lira F., Rosales-León L., Martinez V.M., Ruiz Ordaz B.H. The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen. Biochim Biophys Acta 2006, 1764:815-823.
17. Zhang C., Li K., Shi B., Wang X., Liu X., Qin W., et al. Detection of serum beta(2)-GPI-Lp(a) complexes in patients with systemic lupus erythematosus. Clin Chim Acta 2010, 411:395-399.
18. 2-GPI-Lp(a) complexes and their association with premature atherosclerosis in patients of rheumatoid arthritis. Clin Chim Acta 2011, 412:1332-1336.
19. Wang J.J., Gong J.S., Li H.O., Niu D.M., Han A.Z., Wu J., et al. Lipoprotein(a) complexes with beta2-Glycoprotein I in patients with coronary artery disease. J Atheroscler Thromb 2012, 19:81-89.
20. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diabetes Care 2004, 27(Suppl. 1). S5-10.
21. 2-glycoprotein I: a plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway. Blood 1985, 66:1086-1091.
22. George J., Harats D., Gilburd B., Afek A., Levy Y., Schneiderman J., et al. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999, 99:2227-2230.
23. Song K.H., Ko S.H., Kim H.W., Ahn Y.B., Lee J.M., Son H.S., et al. Prospective study of lipoprotein(a) as a risk factor for deteriorating renal function in type 2 diabetic patients with overt proteinuria. Diabetes Care 2005, 28:1718-1723.
24. Gambino R., Ruiu G., Pagano G., Cassader M. The binding of apolipoprotein H (beta2-Glycoprotein I) to lipoproteins. Prostaglandins Other Lipid Mediat 1999, 57:351-359.
25. Georgiadis A.N., Papavasiliou E.C., Lourida E.S., Alamanos Y., Kostara C., Tselepis A.D., et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment - a prospective, controlled study. Arthritis Res Ther 2006, 8:R82.
26. White D., Fayez S., Doube A. Atherogenic lipid profiles in rheumatoid arthritis. N Z Med J 2006, 119:U2125.
27. Onat A., Can G., Yüksel H. Dysfunction of high-density lipoprotein and its apolipoproteins: new mechanisms underlying cardiometabolic risk in the population at large. Arch Turk Soc Cardiol 2012, 40:368-385.
28. Onat A., Direskeneli H. Excess cardiovascular risk in inflammatory rheumatic diseases: pathophysiology and targeted therapy. Curr Pharm Design 2012, 18:1465-1477.
29. Myasoedova E., Crowson C.S., Kremers H.M., Fitz-Gibbon P.D., Therneau T.M., Gabriel S.E. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann Rheum Dis 2010, 69:1310-1314.
30. Emerging Risk Factors Collaboration, Erqou S., Kaptoge S., Perry P.L., Di Angelantonio E., Thompson A., et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009, 302:412-423.
31. Mora S., Kamstrup P.R., Rifai N., Nordestgaard B.G., Buring J.E., Ridker P.M. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 2010, 56:1252-1260.
32. Smaoui M., Hammami S., Chaaba R., Attia N., Hamda K.B., Masmoudi A.S., et al. Lipids and lipoprotein(a) concentrations in Tunisian type 2 diabetic patients: relationship to glycemic control and coronary heart disease. J Diabetes Complications 2004, 18:258-263.
33. Nakhjavani M., Morteza A., Esteghamati A., Khalilzadeh O., Zandieh A., Safari R. Serum lipoprotein(a) levels are greater in female than male patients with type-2 diabetes. Lipids 2011, 46:349-356.
34. Qasim A.N., Martin S.S., Mehta N.N., Wolfe M.L., Park J., Schwartz S., et al. Lipoprotein(a) is strongly associated with coronary artery calcification in type-2 diabetic women. Int J Cardiol 2011, 150:17-21.
35. Tsimikas S., Mallat Z., Talmud P.J., Kastelein J.J., Wareham N.J., Sandhu M.S., et al. Oxidation-specific biomarkers, lipoprotein(a) and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010, 56:946-955.
36. Marcovina S.M., Albers J.J., Gabel B., Koschinsky M.L., Gaur V.P. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995, 41:246-255.
37. Barlera S., Specchia C., Farrall M., Chiodini B.D., Franzosi M.G., Rust S., et al. Multiple QTL influence the serum Lp(a) concentration: a genome-wide linkage screen in the PROCARDIS study. Eur J Hum Genet 2007, 15:221-227.
38. Romero F.I., Khamashta M.A., Hughes G.R. Lipoprotein(a) oxidation and autoantibodies: a new path in atherothrombosis. Lupus 2000, 9:206-209.
39. Umahara T., Uchihara T., Yamada S., Hashimoto T., Akimoto J., Haraoka J., et al. Differential expression of oxidized/native lipoprotein(a) and plasminogen in human carotid and cerebral artery plaques. Atherosclerosis 2011, 215:392-398.
40. Morishita R., Ishii J., Kusumi Y., Yamada S., Komai N., Ohishi M., et al. Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vascular wall. J Atheroscler Thromb 2009, 16:410-418.
41. Chasman D.I., Paré G. Getting closer to p-selectin. Clin Chem 2009, 55:1051-1052.
42. Zhao S.P., Xu D.Y. Oxidized lipoprotein(a) enhanced the expression of P-selectin cultured human umbilical vein endothelial cells. Thromb Res 2000, 100:501-510.
43. Wang J.J., Zhang C.N., Han A.Z., Gong J.B., Li K. Percutaneous coronary intervention results in acute increases in native and oxidized lipoprotein(a) in patients with acute coronary syndromes and stable coronary artery disease. Clin Biochem 2010, 43:1107-1111.
44. Tsimikas S., Brilakis E.S., Miller E.R., McConnell J.P., Lennon R.J., Kornman K.S., et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005, 353:46-57.